Diabetic Eye Disease Pipeline Therapies Part 3: Brolucizumab & PDS
This discussion with Program Chair Christina Y. Weng, MD, MBA, and Sophie J. Bakri, MD, includes a case study that highlights challenges with managing diabetic eye disease during the COVID era and how longer duration therapies could be beneficial.
Available credits: 0.50
Time to complete: 30 minutes
Released:
Valid until:
If you’ve already completed the activity.
This discussion with Program Chair Christina Y. Weng, MD, MBA, and Sophie J. Bakri, MD, includes a case study that highlights challenges with managing diabetic eye disease during the COVID era and how longer duration therapies could be beneficial.
Drs. Weng and Bakri also converse about the latest data on pipeline therapies for diabetic macular edema, including brolucizumab & PDS.
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Christina Y. Weng, MD, MBA, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Alimera Sciences, Allergan/AbbVie, DORC, Genentech, Novartis, Regeneron Pharmaceuticals, and Regenxbio.
Sophie J. Bakri, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Adverum, Allergan, Alimera, Apellis, Eyepoint Pharmaceuticals, Regenexbio, Genentech, Kala Pharmaceuticals, Novartis, and Roche.
The Evolve staff and planners have no financial relationships with commercial interests.
Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.
The intended audience for this activity is ophthalmologists, retina specialists, and other health care professionals involved in the management of patients with age-related macular degeneration or diabetic retinopathy.
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Genentech, a member of the Roche Group.
Provided by Evolve Medical Education LLC (Evolve).
Supported by an educational grant from Genentech, a member of the Roche Group.
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.
Facebook Comments